Theravance Biopharma Inc (TBPH):企業の財務・戦略的SWOT分析

◆英語タイトル:Theravance Biopharma Inc (TBPH) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH2442170FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Theravance Biopharma Inc (TBPH) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Theravance Biopharma Inc (Theravance Biopharma) is a biopharmaceutical company that discovers, develops, and markets organ-selective medicines for the treatment of inflammation and immune system disorders. The company is investigating its pipeline candidates for the treatment of asthma; neurogenic orthostatic hypotension (nOH); gastrointestinal motility disorders; ulcerative colitis; heart failure; chronic kidney disease (CKD); Crohn’s disease; gastroparesis and concurrent bacteremia. Its Yupelritm (revefenacin) obtained the US FDA approval for the treatment of chronic obstructive pulmonary disease (COPD) and is available in the US. The company has subsidiaries in the US, Ireland and the UK. Theravance Biopharma is headquartered in South San Francisco, California, the US.

Theravance Biopharma Inc Key Recent Developments

Feb 24,2021: Theravance Biopharma reports fourth quarter and full year 2020 financial results and provides business update
Feb 10,2021: Theravance Biopharma to Participate in Upcoming Investor Conferences
Nov 05,2020: Theravance Biopharma reports third quarter 2020 financial results and provides business update
Aug 06,2020: Theravance Biopharma reports second quarter 2020 financial results and provides business update
Jul 06,2020: Theravance Biopharma: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Theravance Biopharma Inc – Key Facts
Theravance Biopharma Inc – Key Employees
Theravance Biopharma Inc – Key Employee Biographies
Theravance Biopharma Inc – Major Products and Services
Theravance Biopharma Inc – History
Theravance Biopharma Inc – Company Statement
Theravance Biopharma Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Theravance Biopharma Inc – Business Description
Business Segment: Collaboration Revenue
Performance
Business Segment: Licensing Revenue
Performance
Business Segment: Product sales
Performance
Business Segment: Viatris Collaboration Agreement
Performance
Geographical Segment: Asia
Performance
Geographical Segment: Europe
Performance
Geographical Segment: The US
Performance
R&D Overview
Theravance Biopharma Inc – Corporate Strategy
Theravance Biopharma Inc – SWOT Analysis
SWOT Analysis – Overview
Theravance Biopharma Inc – Strengths
Theravance Biopharma Inc – Weaknesses
Theravance Biopharma Inc – Opportunities
Theravance Biopharma Inc – Threats
Theravance Biopharma Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Theravance Biopharma Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 24, 2021: Theravance Biopharma reports fourth quarter and full year 2020 financial results and provides business update
Feb 10, 2021: Theravance Biopharma to Participate in Upcoming Investor Conferences
Nov 05, 2020: Theravance Biopharma reports third quarter 2020 financial results and provides business update
Aug 06, 2020: Theravance Biopharma reports second quarter 2020 financial results and provides business update
Jul 06, 2020: Theravance Biopharma: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Jul 02, 2020: Theravance Biopharma appoints Deepika R. Pakianathan, Ph.D. to board of directors
May 06, 2020: Theravance Biopharma, reports first quarter 2020 financial results and provides business update
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Theravance Biopharma Inc, Key Facts
Theravance Biopharma Inc, Key Employees
Theravance Biopharma Inc, Key Employee Biographies
Theravance Biopharma Inc, Major Products and Services
Theravance Biopharma Inc, History
Theravance Biopharma Inc, Subsidiaries
Theravance Biopharma Inc, Key Competitors
Theravance Biopharma Inc, Ratios based on current share price
Theravance Biopharma Inc, Annual Ratios
Theravance Biopharma Inc, Annual Ratios (Cont...1)
Theravance Biopharma Inc, Interim Ratios
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Theravance Biopharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Theravance Biopharma Inc (TBPH):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Laredo Petroleum Inc (LPI):企業の財務・戦略的SWOT分析
    Laredo Petroleum Inc (LPI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Aegion Corp (AEGN):企業の財務・戦略的SWOT分析
    Aegion Corp (AEGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Paratek Pharmaceuticals Inc (PRTK):製薬・医療:M&Aディール及び事業提携情報
    Summary Paratek Pharmaceuticals Inc (Paratek) is a biopharmaceutical company that develops and commercializes therapies based on tetracycline chemistry. Omadacycline (antibiotic), the company’s lead product candidate is an aminomethylcycline which acts against gram-negative, gram-positive, and atypi …
  • Five Prime Therapeutics Inc (FPRX):企業の財務・戦略的SWOT分析
    Five Prime Therapeutics Inc (FPRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Sygnity SA (SGN):企業の財務・戦略的SWOT分析
    Sygnity SA (SGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • ResApp Health Ltd (RAP):企業の製品パイプライン分析
    Summary ResApp Health Ltd (ResApp) formerly, Narhex Life Sciences Limited is a digital health company that develops smartphone applications for the diagnosis and management of respiratory disease. It's digital healthcare solutions assist doctors and patients to diagnose and manage respiratory diseas …
  • Packaging Corporation of America (PKG):企業の財務・戦略的SWOT分析
    Packaging Corporation of America (PKG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • LegoChem Biosciences Inc (141080)-製薬・医療分野:企業M&A・提携分析
    Summary LegoChem Biosciences Inc (LCB) is a drug company that research and develops small molecule drugs. The company’s services include joint and contract research, chemical library package, compound synthesis and sales, and screening services. Its screening services include metabolic stability, pl …
  • Pakistan State Oil Co Ltd (PSO):企業の財務・戦略的SWOT分析
    Pakistan State Oil Co Ltd (PSO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Tech Data Corporation:企業の戦略・SWOT・財務情報
    Tech Data Corporation - Strategy, SWOT and Corporate Finance Report Summary Tech Data Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • British Polythene Industries PLC:企業の戦略・SWOT・財務情報
    British Polythene Industries PLC - Strategy, SWOT and Corporate Finance Report Summary British Polythene Industries PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Petro Welt Technologies AG (O2C):企業の財務・戦略的SWOT分析
    Petro Welt Technologies AG (O2C) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Windflow Technology Limited (WTL):企業の財務・戦略的SWOT分析
    Windflow Technology Limited (WTL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Jacobs Engineering Group Inc (JEC):石油・ガス:M&Aディール及び事業提携情報
    Summary Jacobs Engineering Group Inc (Jacobs) is a professional services company. It offers a diverse range of technical, professional, and construction services. The company's service portfolio includes project; process, scientific and specialty consulting; engineering and construction; and operati …
  • Balfour Beatty plc:企業の戦略・SWOT・財務情報
    Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report Summary Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Daisy IT Group Ltd:企業の戦略的SWOT分析
    Daisy IT Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • GenKyoTex SA (GKTX):製薬・医療:M&Aディール及び事業提携情報
    Summary GenKyoTex SA (GenKyoTex), formerly Genticel SA, is a biopharmaceutical company that develops NOX therapies. The company develops targeted NOX inhibitors and molecule therapeutics that inhibit the NOX family of enzymes. GenKyoTex’s lead product candidate, GKT831, a selective NOX1/4 inhibitor, …
  • Linde AG (LIN)-エネルギー分野:企業M&A・提携分析
    Summary Linde AG (Linde) is a provider of industrial gases and engineering services. The company specializes in the planning, procurement, construction and operation of gas production and processing plants. Linde offers a wide range of compressed and liquefied gases, and chemicals, and offers facili …
  • George Weston Limited (WN):企業の財務・戦略的SWOT分析
    George Weston Limited (WN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Capstone Therapeutics Corp (CAPS):企業の財務・戦略的SWOT分析
    Summary Capstone Therapeutics Corp (Capstone), formerly OrthoLogic Corp, is a biotechnology company that develops and sells novel peptides and other molecules for helping patients with under-served medical conditions. The company develops Apo E mimetic peptide molecule AEM-28 and its analogs that ha …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆